Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Jan 25, 2011

165_ip_2011-01-25_0bfbd37c-21c2-4bf8-a2ee-959793adcca8.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Cheuvreux German Corporate Conference

Frankfurt/Main, January 19, 2011

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

1. Business Update

2. Financials & Outlook

3. Growth Strategy & Summary

Excellent quarter and fully on track for full-year targets

Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
t
h
r
o
w
R
e
e
n
e
v
u		 \$
2
8
8
9
m
,		 \$
5
3
0
8
m
,		 6
%
N
i
t
e
n
c
o
m
e
t
tr
i
bu
ta
b
le
to
F
M
C
A
G
&
Co
K
Ga
A
a		 \$
2
2
5
m		 \$
2
4
8
m		 1
0
%
i
E
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
0
7
6		 \$
0
8
2		 %
9
  • •Strong revenue growth at 7% at constant currency and 6% organic
  • •Very good EBIT-margin development
  • •Resulting in net income growth of 10%

Total revenue increased by 7%cc to \$3,058 m

Continued excellent revenue growth of 9%cc

\$
U
S
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
t
h
r
o
w		 c
c
N
h
A
i
t
o
r
m
e
r
c
a		 1
4
1
7
,		 1
8
6
3
,		 %
7
I
i
l
t
t
n
e
r
n
a
o
n
a		 4
0
6		 5
4
8		 1
3
%		 1
%
7
T
l
t
o
a		 2
1
4
7
,		 2
3
2
1
,		 %
8		 %
9
  • •Very good organic treatment growth of 4.7% globally
  • •Continued strong revenue per treatment development
  • •Treating 210,191 patients in 2,716 clinics

cc = constant currency

Continued improvement of patient outcomes

N
h
A
i
(
U
S
)
t
o
r
m
e
r
c
a		 E
M		 E
A
%
f
t
i
t
o
p
a
e
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 Q
3
2
0
0
9		 Q
3
2
0
1
0
K
/
V
1
2
t
≥		 9
6
%		 9
6
%		 9
%
5		 5
9
%
1
0
1
2
/
H
l
b
i
d
l
e
m
o
g
o
n
g
=
-		 6
%
4		 6
9
%		 3
%
5		 5
4
%
H
l
b
i
1
0
1
3
/
d
l
e
m
o
g
o
n
g
=
-		 8
7
%		 8
8
%		 7
6
%		 6
%
7
A
l
b
i
3
/
d
l
5
≥
u
m
n
g		 8
2
%		 8
2
%		 8
%
7		 8
6
%
P
h
h
3
5
5
5
/
d
l
t
o
s
p
a
e
m
g
-		 %
5
4		 5
%
7		 %
6
0		 6
1
%
H
i
t
l
i
t
i
d
o
s
p
a
a
o
n
a
s
z
y		 1
0
0		 *
9
8		 8
7		 9
4

The hospitalization rates for the US reflects adoption of CMS policy *

Further improved performance in all key metrics

Q
3
2
0
1
0		 T
l
t
o
a		 N
h
A
i
t
o
r
m
e
r
c
a		 I
i
l
t
t
n
e
r
n
a
o
n
a
O
i
t
h
r
g
a
n
c
r
e
v
e
n
u
e
g
r
o
w		 %
7		 %
7		 %
6
S
k
t
t
t
t
t
h
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w		 %
4
7		 %
4
3		 %
5
6
R
t
t
t
e
v
e
n
u
e
p
e
r
r
e
a
m
e
n		 *
\$
3
1
5		 \$
1
6
5
c
c
S
b
3
0
2
0
1
0
t
e
p
e
m
e
r
,
f
N
b
l
i
i
u
m
e
r
o
c
n
c
s		 2
1
6
7
,		 1
8
0
9
,		 9
0
7
G
t
h
r
o
w		 8
%		 3
%		 1
9
%
D
e
n
o
v
o
s		 2
7		 4
2		 3
0

* including Mexico

Stable reimbursement environment

Product growth in North America impacted by mix shift

\$
U
S
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
e
n
e
v
u
(
)
inc
l.
in
te
l r
rn
a
ev
en
ue		 1
0
0
3
,		 1
0
1
8
,		 %
2		 %
4
E
l
t
e
r
n
a
r
e
e
n
e
x
v
u		 7
4
2		 7
3
7		 %
1
-		 %
3
N
h
A
i
t
o
r
m
e
r
c
a		 2
0
9		 2
0
8		 0
%
I
t
t
i
l
n
e
r
n
a
o
n
a		 5
3
3		 5
2
9		 %
1
-		 %
4

cc = constant currency

Product Launches

Liberty Cylcler F250 - Optiflux Delflex – neutral pH 2008 K-Sorb2008 T 5008 S

1. Business Update

2. Financials & Outlook

3. Growth Strategy & Summary

\$
S
U
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 9
M
2
0
1
0		 G
h
t
r
o
w
N
t
e
r
e
e
n
e
v
u		 8
2
1
2
,		 8
8
8
6
,		 *
8
%
O
(
)
t
i
i
E
B
I
T
p
e
r
a
n
g
n
c
o
m
e		 1
2
6
5
,		 1
3
8
5
,		 1
0
%
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
4
5		 1
6
5
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e
n
e
,		 2
2
5		 2
0
6
f
I
b
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 1
0
4
0
,		 1
1
9
7
,		 1
3
%
I
t
n
c
o
m
e
a
e
p
e
n
s
e
x
x		 3
4
5		 4
1
0
T
t
a
r
a
e
x		 %
3
3		 %
3
5
N
t
l
l
i
i
t
t
o
n
-c
o
n
r
o
n
g
n
e
r
e
s		 5
0		 6
2
N
t
i
e
n
c
o
m
e
i
bu
b
le
F
M
C
A
G
&
Co
K
Ga
A
t
tr
ta
to
a		 6
4
5		 7
0
7		 1
0
%

* 8% growth at constant currency, 6% organic growth

Operating cash flow above \$ 1 billion and at 12% of revenue

\$
U
S
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 9
M
2
0
1
0		 G
t
h
r
o
w
1)
O
i
h
f
l
t
p
e
r
a
n
g
c
a
s
o
w		 8
8
0		 1
0
2
7
,
1
2
%
f r
o
ev
e
nu
e		 %
1
7
1)
C
i
l
d
i
t
t
t
a
p
a
e
x
p
e
n
u
r
e
s
n
e
,		 (
3
8
8
)		 (
)
3
3
9
F
h
f
l
r
e
e
c
a
s
o
w		 4
9
2		 6
8
8
8
%
f r
o
ev
e
nu
e		 %
4
0
1)
2)
A
i
i
i
t
f
d
i
i
c
q
u
s
o
n
s
t
t
t
n
e
o
v
e
s
u
r
e
s
,		 (
)
1
0
7		 (
)
2
3
9
1)
2)
F
h
f
l
f
t
i
i
t
i
r
e
e
c
a
s
o
w
a
e
r
a
c
q
s
o
n
s
u
,		 3
8
5		 4
4
9

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

2) Does not include a \$131 m cash out for a short-term bank deposit in Q2 2010 and a cash repayment in form of an inter-company loan of \$ 50 m in Q2 2009

2010 Guidance – Outlook improved

US\$ millions Guidance
Net revenue > \$12,000
Net income
improved
attributable to FMC AG & Co. KGaA		 \$960 - 980
Leverage ratio (Debt/EBITDA) < 2.5
Capital expenditures $$550 - 650$
Acquisitions up to \$500

1. Business Update

2. Financials & Outlook

3. Growth Strategy & Summary

World Leader in Dialysis Services

North America

Latin America

Based on company estimates

We Lead in Every Major Market, Treating More Than 212,068 Patients Worldwide

EMEA

Asia Pacific

* patients including managed clinics

Market Position by Major Product Groups

R
k
1
a
n		 R
k
2
a
n		 R
k
3
a
n
i
D
l
a
e
r
s
y
z		 F
M
E		 G
b
a
m
r
o		 N
i
p
r
o
D
i
l
i
h
i
a
s
s
m
a
c
n
e
s
y		 F
M
E		 G
b
a
m
r
o		 N
i
k
k
i
s
o
H
d
i
l
i
t
t
e
m
o
a
s
s
c
o
n
c
e
n
r
a
e
s
y		 F
M
E		 F
s
o
u		 G
b
a
m
r
o
i
B
l
d
l
o
o
n
e
s		 F
M
E		 G
b
a
m
r
o		 K
i
a
w
a
s
u
m
P
i
l
d
i
l
i
d
t
t
e
r
o
n
e
a
a
y
s
s
p
r
o
u
c
s		 B
t
a
x
e
r		 F
M
E		 P
i
s
a

Produced more than ~85,000,000 Dialyzers in 2009

Development of Dialysis Patient Population

  • Renal failure persists worldwide
  • Dialysis is the primary treatment modality on a global scale
  • The number of global dialysis patients is expected to double by 2020

Market Opportunity by Region

FME's Products and Services by Region

Continued Growth Opportunities

Cheuvreux GCC, Jan 19, 2011 © 2011 Fresenius Medical Care AG & Co. KGaA Page 22

L
d
h
i
e
a
e
r
s
p		 M
i
i
l
b
l
l
d
h
i
i
i
t
t
a
n
a
n
o
u
r
g
o
a
e
a
e
r
s
p
p
o
s
o
n
•
C
i
h
h
f
f
h
d
i
l
i
i
d
t
t
t
t
t
t
o
n
n
u
e
o
s
a
p
e
e
u
u
r
e
o
e
a
y
s
s
n
u
s
r
y
•
Q
l
i
t
a
u
y		 M
i
i
i
l
i
i
d
d
i
t
t
t
a
n
a
n
s
p
e
r
o
r
q
a
n
p
r
o
c
s
a
n
s
e
r
c
e
s
u
u
y
u
v
•
G
h
t
r
o
w		 f
f
B
i
d
i
i
t
t
t
e
n
e
r
o
m
p
r
o
c
n
n
o
a
o
n
s
u
v
•
i
f
i
i
i
T
k
l
h
l
t
t
t
t
t
t
t
a
e
o
p
p
o
r
n
o
n
e
r
n
a
o
n
a
g
r
o
p
o
e
n
a
u
y
w
•
f
f
i
I
d
h
t
t
n
r
o
c
e
n
e
e
r
a
p
o
e
r
n
g
s
u
w
y
•
C
i
i
i
f
i
h
l
d
d
t
t
t
o
n
n
e
o
r
o
n
a
e
p
a
n
s
o
n
o
s
e
r
c
e
a
n
p
r
o
c
r
a
n
g
e
u
z
x
v
u
•
i
i
F
l
n
a
n
c
a		 C
l
d
d
i
t
t
o
n
r
o
c
o
s
a
n
s
p
e
n
n
g
•
S
k
i
i
i
i
t
t
t
t
t
t
t
e
e
a
r
a
c
v
e
n
v
e
s
m
e
n
o
p
p
o
r
u
n
e
s
•
C
i
f
i
b
l
h
t
t
t
t
o
n
n
u
e
p
r
o
a
e
g
r
o
w
m
o
m
e
n
u
m
•

Thank you for your interest in Fresenius Medical Care

Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

All figures are in \$ millions

D
b
t
e		 Q
3
2
0
1
0		 F
Y
2
0
0
9		 F
Y
2
0
0
8		 F
Y
2
0
0
7
S
ho
bo
in
(
in
l.
A
/
R
)
t-
te
r
rm
rro
w
g
s
c
p
ro
g
ra
m		 6
2
3		 3
1
6		 6
8
4		 2
1
7
S
ho
t-
te
bo
ing
fro
la
te
d
t
ies
+
r
rm
rro
s
m
re
p
ar
w		 1
0		 1
0		 1 2
Cu
f
t p
t
ion
lon
te
de
b
t a
d
i
ta
l
lea
b
l
ig
t
ion
+
rre
n
or
o
g-
rm
n
ca
p
se
o
a
s		 1
5
8		 1
5
8		 4
5
5		 8
5
Cu
t p
t
ion
f
tru
t p
fe
d
i
t
ies
+
rre
n
or
o
s
re
rre
se
cu
r		 6
3
4		 6
7
0
Lo
de
b
d
i
l
lea
b
l
ig
ion
-te
t a
ta
t
+
ng
rm
n
ca
p
se
o
a
s,
les
t p
t
ion
s c
ur
re
n
or		 4,
3
1
1		 4,
4
2
8		 3,
9
5
7		 4,
0
0
4
fe
Tr
t p
d
i
t
ies
+
us
re
rre
se
cu
r		 - 6
5
6		 6
4
1		 6
6
4
To
ta
l
de
b
t
=		 5,
7
3
6		 5,
5
6
8		 5,
7
3
8		 5,
6
4
2
E
B
I
T
D
A		 Q
3
2
0
1
0		 1
)
F
Y
2
0
0
9		 F
Y
2
0
0
8		 F
Y
2
0
0
7
(
)
La
t
tw
lve
t
hs
t
in
in
E
B
I
T
s
e
m
on
o
p
er
a
g
co
m
e		 1,
8
7
6		 1,
6
9
7		 1,
6
7
2		 1,
5
8
0
La
t
tw
lve
t
hs
de
ia
t
ion
d
t
iza
t
ion
+
s
e
m
on
p
re
c
a
n
am
or		 4
9
2		 4
4
3		 4
1
6		 3
6
3
No
h
ha
+
n-
ca
s
c
rg
es		 4
8		 4
8		 4
4		 4
1
E
B
I
T
D
A
(
l
ize
d
)
an
nu
a
=		 2,
4
1
6		 2,
1
8
8		 2,
1
3
2		 1,
9
8
4
C
(
)
i
l
d
i
t
t
t
a
p
a
e
p
e
n
r
e
n
e
x
u		 9
M
2
0
1
0		 9
M
2
0
0
9		 Q
3
2
0
1
0		 Q
3
2
0
0
9
f p
Pu
ha
ty
la
t a
d
ip
t
rc
s
e
o
ro
p
e
r
p
n
n
e
q
u
m
e
n
,		 (
)
3
5
0		 (
)
3
9
8		 (
)
1
2
3		 (
)
1
4
5
Pr
d
fro
le
f p
ty
la
t a
d
ip
t
o
c
e
e
s
m
s
a
o
ro
p
e
r
p
n
n
e
q
u
m
e
n
-
,		 1
1		 1
0		 2 6
C
i
l
d
i
(
)
t
tu
t
a
p
a
e
x
p
e
n
r
e
n
e
=		 (
3
3
9
)		 (
3
8
8
)		 (
1
2
1
)		 (
1
3
9
)

1) Excluding restructuring costs and in-process R&D

Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

E
l
R
t
x
e
r
n
a
e
v
e
n
u
e

All figures are in \$ millions

A
i
i
i
(
)
t
t
c
q
s
o
n
s
n
e
u		 9
M
2
0
1
0		 9
M
2
0
0
9		 Q
3
2
0
1
0		 Q
3
2
0
0
9
Ac
is
i
t
io
d
in
tm
t a
d
t p
ha
f
in
ta
i
b
le
ts
q
u
ns
a
n
ve
s
e
n
n
ne
u
rc
s
e
s
o
ng
a
s
s
e		 (
3
7
8
)		 (
1
0
9
)		 (
8
8
)		 (
2
7
)
fro
Pr
d
d
ive
t
i
tu
o
c
e
e
s
m
s
re
s		 8 5
2		 1 1
Ac
is
i
io
d
in
f
d
ive
i
t
tm
ts
t o
t
tu
q
ns
a
n
ve
s
e
n
ne
s
re
s
u
,		 (
3
0
)
7		 (
)
5
7		 (
8
)
7		 (
2
6
)
In
tm
t,
t o
f r
ts
ve
s
e
n
ne
e
p
ay
m
e
n		 1
3
1		 (
5
0
)		 - -
Ac
is
i
t
io
t o
f
d
ive
t
i
tu
q
u
ns
ne
s
re
s
,		 (
2
3
9
)		 (
1
0
7
)		 (
8
7
)		 (
2
6
)

cc = constant currency

Q
3
2
0
1
0		 C
l
i
i
n
c
s		 P
i
t
t
a
e
n
s		 T
t
t
r
e
a
m
e
n
s
(
in
i
l
l
io
)
m
ns
T
t
l
o
a		 2
7
1
6
,		 2
1
0
1
9
1
,		 2
3
4
G
t
h
r
o
w		 8
%
+		 9
%
+		 7
%
+
N
h
A
i
t
o
r
m
e
r
c
a		 1
8
0
9
,		 1
3
4
6
5
7
,		 1
5
5
G
h
t
r
o
w		 3
%
+		 4
%
+		 %
5
+
I
t
t
i
l
n
e
r
n
a
o
n
a		 9
0
7		 7
4
4
4
5
,		 7
9
G
h
t
r
o
w		 1
9
%
+		 2
0
%
+		 1
1
%
+
E
r
o
p
e
u		 4
8
2		 3
6
8
7
1
,		 4
0
L
i
A
i
t
a
n
m
e
r
c
a		 1
9
1		 2
1
9
3
4
,		 2
5
A
i
P
i
f
i
s
a
a
c
c
-		 2
3
4		 1
6
4
0
5
,		 1
4

Operating Margin Development

9M 2010 Operating Margin Development

9
M
2
0
0
9		 9
M
2
0
1
0		 G
t
h
r
o
w
R
e
e
n
e
v
u		 \$
8
2
1
2
m
,		 \$
8
8
8
6
m
,		 %
8
N
i
t
e
n
c
o
m
e
C
G
&
Co
Ga
t
tr
i
bu
ta
b
le
to
F
M
A
K
A
a		 \$
5
6
4
m		 \$
7
0
7
m		 1
0
%
i
E
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
2
1
6		 \$
2
3
5		 %
9

•Strong revenue growth at 8% at constant currency and 6% organic

•Continued excellent cash flow development

Total revenue increased by 8%cc to \$8,886 m

Excellent revenue growth globally

\$
U
S
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 M
9
2
0
1
0		 G
h
t
r
o
w		 c
c
N
h
A
i
t
o
r
m
e
r
c
a		 4
9
9
5
,		 5
4
4
1
,		 9
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 1
1
2
9
,		 5
1
2
7
,		 1
3
%		 1
2
%
T
l
t
o
a		 6
1
2
4
,		 6
7
1
6
,		 %
1
0		 %
9
  • •Good organic treatment growth of 4.4% globally
  • •Continued strong revenue per treatment development

cc = constant currency

Total revenue growth year to date on target

\$
U
S
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 9
M
2
0
1
0		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
e
n
e
v
u
(
inc
l.
in
te
l r
)
rn
a
ev
en
ue		 2
8
1
6
,		 2
9
8
0
,		 6
%		 5
%
E
l
t
e
r
n
a
r
e
e
n
e
x
v
u		 2
0
8
8
,		 2
1
0
7
,		 %
4		 %
3
N
h
A
i
t
o
r
m
e
r
c
a		 6
0
5		 6
1
7		 2
%
I
t
t
i
l
n
e
r
n
a
o
n
a		 1
4
8
3
,		 1
5
5
3
,		 5
%		 4
%

cc = constant currency

\$
U
S
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
t
h
r
o
w
N
t
e
r
e
v
e
n
u
e		 2
8
8
9
,		 3
0
5
8
,		 *
6
%
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 4
5
1		 4
9
3		 9
%
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
5
6		 1
6
1
I
t
t
t
n
e
r
e
s
e
p
e
n
s
e
n
e
x
,		 7
5		 7
0
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 3
7
6		 4
2
3		 1
2
%
I
t
n
c
o
m
e
a
x
e
x
p
e
n
s
e		 1
3
1		 1
5
3
T
t
a
x
r
a
e		 3
%
5		 3
6
%
N
t
l
l
i
i
t
t
o
n
-c
o
n
r
o
n
g
n
e
r
e
s		 2
0		 2
2
N
i
t
e
n
c
o
m
e
t
tr
i
bu
ta
b
le
to
F
M
C
A
G
&
Co
K
Ga
A
a		 2
2
5		 2
4
8		 1
0
%

* 7% growth at constant currency, 6% organic growth

Continued excellent cash collection

Very Strong operating cash flow performance

\$
U
S
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
h
t
r
o
w
1)
O
f
t
i
h
l
p
e
r
a
n
g
c
a
s
o
w		 4
4
3		 3
8
4
1
3
%
f r
o
ev
e
nu
e		 1
3
%
-
1)
C
i
l
d
i
t
t
a
p
a
e
p
e
n
r
e
s
t
x
u
n
e
,		 (
)
1
3
9		 (
)
1
2
1
f
F
h
l
r
e
e
c
a
s
o
w		 3
0
4		 2
6
3
9
%
f r
o
ev
e
nu
e		 1
4
%
-
1)
A
i
i
i
t
f
t
d
i
t
i
t
c
q
u
s
o
n
s
n
e
o
v
e
s
u
r
e
s
,		 (
2
6
)		 (
)
8
7
1)
F
h
f
l
f
i
i
i
r
e
e
c
a
s
o
t
t
w
a
e
r
a
c
q
u
s
o
n
s
,		 2
8
7		 1
6
7

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

Debt/EBITDA ratio improved further

* including non-cash charges and in 2007 excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics. A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

Industry's only vertically integrated provider

Global Strategy - Services – Areas to Improve Dialysis Outcomes

F
Y
2
0
1
0
R
l
t
e
s
s
u		 – A
l
M
i
F
b
2
3
2
0
1
1
t
t
n
a
s
e
e
n
g
e
r
a
r
y
u
y
,
,
Q
1
2
0
1
1
R
l
t
e
s
u
s		 – C
f
C
l
l,
M
4
2
0
1
1
o
n
e
r
e
n
c
e
a
a
y
,
Q
2
2
0
1
1
R
l
t
e
s
u
s		 – C
C
f
l
l,
A
3
2
0
1
1
t
o
n
e
r
e
n
c
e
a
u
g
u
s
,
Q
3
2
0
1
1
R
l
t
e
s
s
u		 – C
C
f
l
l,
N
b
2
2
0
1
1
o
n
e
r
e
n
c
e
a
o
e
m
e
r
v
,

Fresenius Medical Care AG & Co. KGaA (Frankfurt FME / NYSE FMS) Investor RelationsElse-Kröner-Str. 161352 Bad Homburg v.d.H.

Oliver Maier

Head of Investor Relations & Corp. Comm. Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 E-mail: [email protected]

Gerrit JostTel.: +49-(0)6172-609-5216 Fax.: +49-(0)6172-609-2301 E-mail: [email protected] Terry L. Morris

Tel.: +1-800-948-2538Fax.: +1-615-345-5605E-mail: [email protected]

More from Fresenius Medical Care AG & Co. KGaA

Regulatory Filings 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.